Analysis

Atossa Therapeutics, Inc. (ATOS) Stock Analysis

Atossa Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ATOS.

websiteATOS/analysis/ATOS

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ATOS.

Stock profile

Ticker

ATOS

Asset type

Stock

Market cap

$20.0M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Atossa Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ATOS primary listing
  • YAG
  • A2JJ99
  • A41ZVB

Latest Atossa Therapeutics, Inc. news

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high u...

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high u...

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of signif...

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular D...

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of signif...

Research sections

Valuation

Review valuation context for Atossa Therapeutics, Inc..

Future growth

Review future growth context for Atossa Therapeutics, Inc..

Past performance

Review past performance context for Atossa Therapeutics, Inc..

Financial health

Review financial health context for Atossa Therapeutics, Inc..

Dividend

Review dividend context for Atossa Therapeutics, Inc..

Management

Review management context for Atossa Therapeutics, Inc..

Ownership

Review ownership context for Atossa Therapeutics, Inc..

Other information

Review other information context for Atossa Therapeutics, Inc..

Community

Review community context for Atossa Therapeutics, Inc..